China SXT Pharmaceuticals (SXTC) Long-Term Investments (2019 - 2022)

China SXT Pharmaceuticals (SXTC) has reported Long-Term Investments for 4 consecutive years, with $1.6 million the latest figure, recorded in Q3 2022.

• Quarterly Long-Term Investments changed 0.0% year-over-year to $1.6 million in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $1.6 million (changed 0.0% YoY) and the FY2022 annual result came in at $1.6 million, changed 0.0% from the prior year.
• Long-Term Investments held at $1.6 million in Q3 2022 per SXTC's latest filing, from $1.6 million in the prior quarter.
• Over the last five years, Long-Term Investments for SXTC reached as high as $3.5 million in Q3 2019 and fell as low as $1.6 million in Q1 2020.
• A 4-year average of $1.9 million and a median of $1.6 million in 2021 frame the typical range for Long-Term Investments.
• Annual changes were most pronounced in 2020 — Long-Term Investments plunged 54.03% — and 2021, when it rose 0.86%.
• Year by year, Long-Term Investments stood at $3.5 million in 2019, then slumped by 54.03% to $1.6 million in 2020, then slipped by 1.68% to $1.6 million in 2021, then changed by 0.0% to $1.6 million in 2022.
• According to Business Quant data, Long-Term Investments over the past three periods registered $1.6 million, $1.6 million, and $1.6 million for Q3 2022, Q1 2022, and Q3 2021 respectively.